Layoffs, investigation what’s up at Abbott?
Since most people aren’t aware of Abbott’s history in CGM let’s go backward before we go forward. In February of 2004 when Abbott acquired Therasense for $1.2 Billion hidden in this deal was the Navigator. Keep in mind that back in 2004 BGM ruled the glucose monitoring world and CGM was still a dream. Yet CGM was coming, and the Navigator was considered the best of the bunch.
In June 2005 Abbott submits the Navigator to the FDA but with a twist. Rather than go for an adjunct indication which the FDA was comfortable with they . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.